Why Is QUEST DIAGNOSTICS IN (DGX) Stock Up Today?

DGX stock surged 10.12% to $231.24 in early trading on July 23, 2026, driven by the company's second-quarter financial results and raised full-year guidance. Quest Diagnostics reported non-GAAP earnings per share of $3.12, exceeding estimates by $0.30, and revenue of $3.04 billion, which beat expectations by $70 million. The company also announced an upward revision of its 2026 guidance for both revenue and adjusted EPS.

What Happened

Quest Diagnostics delivered strong Q2 2026 performance, with revenue up 10.2% year-over-year to $3.04 billion and organic revenue growth of 10.0%. Adjusted diluted EPS reached $3.12, up 15.0% from the prior year. The company raised its full-year 2026 adjusted EPS guidance from $10.63 to $10.83 to a new range of $11.05 to $11.25. It also lifted its revenue guidance from $11.78 billion to $11.9 billion to $11.95 billion to $12.05 billion. The 8-K filing disclosed these results and the updated guidance, confirming the company's confidence in its growth trajectory.

What The Data Shows

The stock opened with a 6.8% gap up from the prior close, reaching $224.00 at the market open. It reached a session high of $237.78 within the first 35 minutes of trading. Volume was 0.6 million shares, slightly above the 3-month average. The stock has traded between $165.78 and $219.20 over the past 52 weeks, and currently trades at a P/E ratio of 23.2 with a market cap of $22.9 billion. Recent insider transactions included two sales totaling $3.6 million over the last 90 days, while congressional trades included several purchases by Donald J. Trump and Alan Armstrong.

What To Watch

With the Q2 2026 earnings already reported and guidance raised, investors will now focus on how the company executes against its updated targets. The next key event will be the release of Q3 2026 results in October 2026. Coverage of the company's performance has expanded in recent days, with six stories published across five sources in the last 36 hours.